Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
Public ClinicalTrials.gov record NCT00684177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.
Study identification
- NCT ID
- NCT00684177
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 508 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Months and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2008 (Type not available)
- Primary completion
- Oct 2009 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Nov 23, 2016
2008 – 2009
United States locations
- U.S. sites
- 32
- U.S. states
- 16
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tucson | Arizona | 85705 | — |
| GSK Investigational Site | Anaheim | California | 92804 | — |
| GSK Investigational Site | Fresno | California | 93710 | — |
| GSK Investigational Site | Irvine | California | 90620 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Sacramento | California | 95825 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80904 | — |
| GSK Investigational Site | Deerfield Beach | Florida | 33441 | — |
| GSK Investigational Site | Hollywood | Florida | 33023 | — |
| GSK Investigational Site | Miami | Florida | 33144 | — |
| GSK Investigational Site | Miami | Florida | 33155 | — |
| GSK Investigational Site | Orlando | Florida | 32712 | — |
| GSK Investigational Site | Panama City | Florida | 32401 | — |
| GSK Investigational Site | Tampa | Florida | 33606 | — |
| GSK Investigational Site | Vero Beach | Florida | 32960 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Arlington Heights | Illinois | 60005 | — |
| GSK Investigational Site | Kansas City | Kansas | 66160 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Teaneck | New Jersey | 07666 | — |
| GSK Investigational Site | Brooklyn | New York | 11218 | — |
| GSK Investigational Site | Brooklyn | New York | 11229 | — |
| GSK Investigational Site | East Syracuse | New York | 13057 | — |
| GSK Investigational Site | Johnson City | New York | 13790 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45246 | — |
| GSK Investigational Site | Norristown | Pennsylvania | 19401 | — |
| GSK Investigational Site | Uniontown | Pennsylvania | 15401 | — |
| GSK Investigational Site | Greenville | South Carolina | 29615 | — |
| GSK Investigational Site | Houston | Texas | 77036 | — |
| GSK Investigational Site | Bountiful | Utah | 84010 | — |
| GSK Investigational Site | Vienna | Virginia | 22180 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00684177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 23, 2016 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00684177 live on ClinicalTrials.gov.